Navigation Links
Gene therapy kills breast cancer stem cells, boosts chemotherapy
Date:9/12/2011

periments, the CMV-BikDD also invaded and destroyed normal cells, while the VISA-Claudin4-BikDD did not.

Agent energizes lapatinib, other drugs

BikDD made HER2-positive breast cancer cells more sensitive to lapatinib when all three Bcl-2 proteins were inhibited but not when they were inhibited separately. HER2-positive breast cancer is a particularly aggressive type that makes too much human epidermal growth factor 2; it accounts for about 20 percent of breast cancers. BikDD also sensitized EGFR+ (epidermal growth factor positive) breast cancer cells to lapatinib and several other breast cancer cells lines to paclitaxel.

Moving discovery forward

Hung said this approach is promising for breast cancer treatment, especially recurrent disease.

"VISA-claudin4-BikDD gene therapy may provide an effective strategy to inhibit breast tumor growth," he said. "It demonstrates virtually no toxicity in normal cells and produces a profound killing effect in multiple breast cancer cell lines and synergy with other agents."

Hung said the next step is to move VISA-claudin4-BikDD into a Phase I clinical trial to test its effect on patients with breast cancer.


'/>"/>

Contact: Scott Merville
smerville@comcast.net
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Game-changing project combines anxiety therapy and video games
2. Targeting a cure: Research looks at developing a bulls-eye therapy to combat lung cancer
3. Popular herbal supplements may adversely affect chemotherapy treatment
4. Genetically engineered spider silk for gene therapy
5. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Mice point to a therapy for Charcot-Marie-Tooth disease
7. Engineering excitable cells for studies of bioelectricity and cell therapy
8. Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies
9. Plenary speakers address challenges in the delivery of sustained antiretroviral therapy in developing countries, call for social scientists to take their place at the HIV/AIDS policy-making table, and stress the need for a long-term response to AIDS
10. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
11. Study uses new stem cell therapy in patients up to 19 days after stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Leaders within the U.S. biomedical device industry unveiled today ... enhance the development of devices with great clinical utility, ... become a key component of the nation,s drive to ... access to device innovation that improves human health, the ...
... OF PRUSSIA, Pa., June 16, 2011 Omnicare Clinical Research, ... re-branding of the company under the name Theorem Clinical Research. ... separation from its former parent company in a deal that ... private equity firm based in Providence, R.I., acquired the CRO ...
... eruption in early June, several NASA satellites have captured images ... Volcano called Puyehue-Cordn Caulle and have tracked it around the ... image gallery that shows the progression of the plume around ... includes the Puyehue volcano, the Cordn Caulle rift zone and ...
Cached Biology News:U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 2U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 3U.S. Biomedical Leaders Present a New National Device Innovation Strategy Based on "Value-driven Engineering" 4Omnicare Clinical Research Re-Brands as Theorem Clinical Research 2Omnicare Clinical Research Re-Brands as Theorem Clinical Research 3NASA satellite gallery shows Chilean volcano plume moving around the world 2NASA satellite gallery shows Chilean volcano plume moving around the world 3
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Finesse Solutions, LLC, a,manufacturer of measurement and control ... its new sales and service center in,Northborough, MA, in ... Solutions is converting its Irvine, CA facility to a,service ... also plans on,opening a European sales and service center ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, today announced that it will host a ... 2008, at 9:00 am Eastern Time (2:00 pm,Central ... full year 2007,financial results. Micromet anticipates releasing its ...
... PharmAthene, Inc., a,biodefense company specializing in the ... biological threats, announced,today that it has completed the ... spectrum chemical nerve agent prophylaxis., The PK ... used the final,pegylated version of rBChE for the ...
Cached Biology Technology:Finesse Solutions Expands by Opening Sales and Service Centers 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results 2PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 2PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 3PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 4
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... 4,600 to Over 3 Million Genotypes Per ... capable of performing 4,600 to over 3 ... GenomeLab family of products*, this automated, scalable, ... SNPs in each well of an arrayed ...
... These protein size markers are a mixture ... 16 to 100 kDa. The markers provide ... gels after staining with Coomassie blue. Because ... II sequence, the markers can also be ...
... solid. A nucleoside antibiotic that inhibits ... of N-glycosidic protein-carbohydrate linkages. Active ... yeasts, fungi, and viruses. Inhibits the ... human T-lymphoblastoid cells. Also inhibits thrombin-induced ...
Biology Products: